Photodynamic therapy with verteporfin in the treatment of exudative idiopathic polypoidal choroidal vasculopathy

To determine the safety and efficacy of photodynamic therapy with verteporfin (V-PDT) in the treatment of exudative idiopathic polypoidal choroidal vasculopathy (IPCV) lesions that were not suitable for laser photocoagulation. This was a prospective, open label study in two centers involving 30 cons...

Full description

Saved in:
Bibliographic Details
Published in:European journal of ophthalmology 2006-09, Vol.16 (5), p.695-704
Main Authors: Mauget-Faÿsse, M, Quaranta-El Maftouhi, M, De La Marnièrre, E, Leys, A
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Choroid - blood supply
Choroid Diseases - drug therapy
Choroid Diseases - pathology
Exudates and Transudates
Female
Fluorescein Angiography
Follow-Up Studies
Fundus Oculi
Humans
Male
Middle Aged
Peripheral Vascular Diseases - drug therapy
Peripheral Vascular Diseases - pathology
Photochemotherapy - methods
Photosensitizing Agents - therapeutic use
Porphyrins - therapeutic use
Prospective Studies
Tomography, Optical Coherence
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To determine the safety and efficacy of photodynamic therapy with verteporfin (V-PDT) in the treatment of exudative idiopathic polypoidal choroidal vasculopathy (IPCV) lesions that were not suitable for laser photocoagulation. This was a prospective, open label study in two centers involving 30 consecutive patients (31 eyes) diagnosed with exudative IPCV using fluorescein angiography (FA), indocyanine green angiography (ICGA), and optical coherence tomography (OCT). All patients underwent complete ophthalmologic examination including best-corrected visual acuity (VA) measurement, contrast sensitivity (CS) testing, FA, ICGA, and OCT. OCT was used to assess the stage of the polypoidal dilations (active or scarred) and the evolution of the signs associated with exudation. Study patients were treated with V-PDT and followed up at 6 weeks and 3, 6, and 12 months. Re-treatment was applied, at an interval of 3 months, until there was an absence of leakage on FA and hyperfluorescence on ICGA. Thirty eyes (29 patients) completed the 12 months post-treatment visit and were retained for further analysis. The mean number of V-PDT treatments was 2.5 (SD 1.1). At 12 months post-treatment, the mean foveal thickness had significantly (p
ISSN:1120-6721
1724-6016
DOI:10.1177/112067210601600506